MedPath

rTMS Treatment of Primary Progressive Aphasia

Not Applicable
Completed
Conditions
Repetitive Transcranical Magnetic Stimulation
Primary Progressive Aphasia
Interventions
Device: Magstim rTMS
Registration Number
NCT04431401
Lead Sponsor
Peking Union Medical College Hospital
Brief Summary

Primary Progressive Aphasia (PPA) is a neurodegenerative disease in which language function is gradually and progressively impaired. Patients will eventually be disabled in communication and have cognition deficits, which put a heavy burden not only on their families but also on the whole society. However, no effective treatment for PPA has been explored so far. The current clinical randomized trial is to study the safety and efficacy of repetitive Transcranial Magnetic Stimulation (rTMS) for the treatment of PPA. Also, multi-modality of neuroimaging techniques, such as functional MRI and PET will be used to investigate brain network changing in this procedure.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
40
Inclusion Criteria
  • Clinical diagnosis of PPA
Exclusion Criteria
  • Scored below 15 on the mini-mental state exam (MMSE)
  • history of seizures or unexplained loss of consciousness
  • pregnancy
  • surgical breach of the skull
  • MRI contraindication

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
sham treatment groupMagstim rTMSThe control group is to receive sham treatment. The device is the same as the one used in the real treatment group.
rTMS treatment groupMagstim rTMSThe participants will be divided into the rTMS treatment group and the sham treatment group by means of randomized methods.The protocol of the treatment is to use rTMS with high frequency 10/20Hz 120%RMT 20 times for one month. The device is Magtism rTMS made in London, UK
Primary Outcome Measures
NameTimeMethod
Western Aphasia Battery (WAB) Word recognition1 month, 3 months and 6 months after the treatment

Assessment of the reading. Scores range from 0 to 60. Higher scores means better outcome.

Boston naming test evaluation1 month, 3 months and 6 months after the treatment

Assessment of the language production. Scores range from 0 to 30. Higher scores means better outcome.

Western Aphasia Battery (WAB) Repetition1 month, 3 months and 6 months after the treatment

Assessment of the repetition ability. Scores range from 0 to 100. Higher scores means better outcome.

Western Aphasia Battery (WAB) Speech fluency1 month, 3 months and 6 months after the treatment

Assessment of the language production. Scores range from 0 to 20. Higher scores means better outcome.

Syntax comprehension part of Bilingual aphasia test (Standard Modern Chinese Version)1 month, 3 months and 6 months after the treatment

Assessment of the grammar ability. Scores range from 0 to 50. Higher scores means better outcome.

Secondary Outcome Measures
NameTimeMethod
functional connectivity map (FC map)1 month, 3 months and 6 months after the treatment

Functional Connectivity was examined using a seed-based voxel-wise correlation approach. The language related brain areas, such as Broca Area and Wernicke Area, were defined as the regions of interest (ROI). Pearson's correlation analysis between the time course of the ROI and that of every voxel in the whole brain was computed for a map of correlation coefficients, which were Fisher's z-transformed and called as z-FC maps. This outcome measurement, the z-FC map, is not numeric data. Z-FC map is a radiographic imaging measurement.

Standardized Uptake Value (SUV)1 month, 3 months and 6 months after the treatment

PET parameter to evaluate brain metabolism

Trial Locations

Locations (1)

Peking Union Medical College Hospital

🇨🇳

Beijing, Beijing, China

© Copyright 2025. All Rights Reserved by MedPath